ADAP Adaptimmune Therapeutics plc

5.77
-0.1  -2%
Previous Close 5.87
Open 5.75
Price To Book 4.04
Market Cap 750,670,693
Shares 130,098,907
Volume 1,374,901
Short Ratio
Av. Daily Volume 558,069
Stock charts supplied by TradingView

NewsSee all news

  1. Adaptimmune Reports Q1 Financial Results

    - Upfront payment of $50m received from Astellas and approximately $90m offering completed -             - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug Designation positive opinion for ADP-A2M4 in

  2. SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting

    - Edited stem-cell derived T-cells can kill MAGE-A4+ cancer targets in vitro - - T-cell receptor expression edited in to stem cells - a milestone to build cell banks for clinical use - PHILADELPHIA and OXFORDSHIRE,

  3. Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020

    - The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 29, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy

  4. Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency's (EMA)

  5. Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update

    - Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 - - Encouraging demonstration of the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 summary at ASCO May 29, 2020. 12-month durability data from patients with synovial sarcoma due 2H 2020.
MAGE-A4 (ADP-A2M4) (ASCO)
Soild tumors
Phase 1 presentation at ILC August 25-28, 2020.
AFP (ADP-A2AFP) (ILC)
Hepatocellular carcinoma
Phase 1 enrolment completed 2019.
MAGE-A10 (ADP-A2M10)
Non-Small Cell Lung Cancer (NSCLC)
Phase 2 data due 2021.
MAGE-A4 (SPEARHEAD‑1)
Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)
Phase 1 dose escalation cohort update due 2H 2020.
MAGE-A4 (ADP-A2M4CD8 - SURPASS)
Soild tumors

Latest News

  1. Adaptimmune Reports Q1 Financial Results

    - Upfront payment of $50m received from Astellas and approximately $90m offering completed -             - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug Designation positive opinion for ADP-A2M4 in

  2. SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting

    - Edited stem-cell derived T-cells can kill MAGE-A4+ cancer targets in vitro - - T-cell receptor expression edited in to stem cells - a milestone to build cell banks for clinical use - PHILADELPHIA and OXFORDSHIRE,

  3. Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020

    - The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 29, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy

  4. Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency's (EMA)

  5. Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update

    - Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 - - Encouraging demonstration of the

  6. Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report financial results for the Full Year /

  7. Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Gavin Wood as

  8. Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters' Option to Purchase Additional American Depositary Shares

    PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune") (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announced that the

  9. Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares

    PHILADELPHIA, Pa. and OXFORD, United Kingdom, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune")(NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its

  10. Synovial Sarcoma Treatment Market will Experience a Noticeable growth During the Forecast Period 2019 – 2024

    HTF Market Intelligence/Press Release/- This intelligence report provides a comprehensive analysis of the Synovial Sarcoma Treatment Market. This includes Investigation of past progress, ongoing market scenarios, and

  11. Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares

    PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ("Adaptimmune")(NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an

  12. Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

    PHILADELPHIA, Pa. and OXFORD, UK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American

  13. Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

    - Agreement covers the co-development and co-commercialization of up to three T-cell therapies - - Agreement leverages Astellas' Universal Donor Cell Platform and Adaptimmune's stem-cell derived allogeneic T-cell

  14. Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, today announced the appointment of Dr. Elliot Norry

  15. Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

    - Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers - - Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid

  16. Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has received Regenerative

  17. Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma

    - Clinical responses in seven out of 14 patients with synovial sarcoma by RECIST 1.1 - - Clinical benefit in 13 out of 14 patients - - One RECIST response maintained for more than 9 months after SPEAR T-cell infusion -

  18. Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update

    - Clinical responses with ADP-A2M4 in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out of 12 patients - - ADP-A2M4 granted Orphan Drug Designation for treatment of soft tissue

  19. Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Third

  20. Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune's Cell Therapies

    PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, and Cryoport, Inc.

  21. Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, announces the appointment of Michael Garone as

  22. Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, presented updated data from patients with

  23. United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announced that the United States Food and

  24. Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, and Noile-Immune Biotech, Inc., Tokyo, Japan, a